Hanall Biopharma (009420) Stock Price, Fundamentals & Analysis

What 009420 does

Hanall Biopharma (009420) is a stock listed on the Korea Exchange in the Healthcare sector, specifically in the Drug Manufacturers – Specialty & Generic industry. The company manufactures and sells pharmaceutical products in South Korea and internationally, with a broad portfolio that includes prescription drugs and over-the-counter treatments for conditions ranging from diarrhea and chronic hepatitis to osteoporosis, prostate cancer, and diabetes. It is headquartered in Daejeon, South Korea, and employs 287 people.

Key numbers explained

• 46,600 KRW is the current share price, representing the latest trading value of one share.
• +1.42% is the price change today, showing the percentage move relative to the previous close.
• 2.37T KRW is the market capitalization, the total value of all outstanding shares; at this size, Hanall Biopharma is a large-cap stock and part of the KOSPI 200.
• 418.1 is the forward P/E ratio, which divides the share price by expected future earnings; a high figure can indicate that investors expect strong growth or that earnings are currently depressed.
• 0% is the share of earnings paid out as dividends, meaning the company currently pays no dividend yield.
• 0.93 is the beta, a measure of volatility relative to the market; a beta below 1 suggests the stock tends to move less than the overall market.
• 31,350 – 73,000 is the 52-week price range, showing the lowest and highest prices over the past year.
• 42.1% is the price change over the last 52 weeks, the total return from one year ago to today.
• 162.66B KRW is the trailing 12-month revenue, the total sales over the past twelve months.
• 8.8% is the year-over-year revenue growth, indicating how much top-line sales have increased compared with the same period a year earlier.
• -15.3% is the profit margin, showing that the company currently operates at a net loss relative to revenue.
• 12.3% is the operating margin, reflecting profitability from core operations before interest and taxes.
• -15.7% is the return on equity, a measure of how effectively the company generates profit from shareholders’ equity.
• 27.8% is the debt-to-equity ratio, indicating the proportion of debt financing relative to equity.

What to watch

Investors tracking Hanall Biopharma (009420) may want to follow the broader Healthcare sector and peer companies such as Chong Kun Dang (185750), Green Cross (006280), SK Biopharm (326030), Samsung Biologics (207940), Daewoong Pharmaceutical (069620), Yuhan (000100), and Celltrion (068270). Regulatory decisions, drug approval cycles, and changes in raw material costs are general factors that can affect drug manufacturers. The company’s debt-to-equity ratio of 27.8% is a moderate level of leverage that is worth monitoring alongside its operating margin of 12.3% and its negative profit margin of -15.3%. For a wider view of the market, see Korea Exchange stocks or the full stocks directory.